Evidence map›Paper›PMID 38361690›Full record

ArticleCureus2024

Tandem T:Slim X2 Insulin Pump Use in Clinical Practice Among Pregnant Individuals With Type 1 Diabetes: A Retrospective Observational Cohort Study.

Neeharika Nandam, Stephen Thung, Kartik K Venkatesh, Steven Gabbe, Jianing Ma, Jing Peng, Kathleen Dungan, Elizabeth O Buschur

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Neeharika NandamDepartment of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, USA.
Stephen ThungDivision of Maternal Fetal-Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, Bridgeport, USA.
Kartik K VenkateshDepartment of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Ohio State University Wexner Medical Center, Columbus, USA.
Steven GabbeDepartment of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Ohio State University Wexner Medical Center, Columbus, USA.
Jianing MaCenter for Biostatistics, Ohio State University Wexner Medical Center, Columbus, USA.
Jing PengCenter for Biostatistics, Ohio State University Wexner Medical Center, Columbus, USA.
Kathleen DunganDivision of Endocrinology, Diabetes, and Metabolism, Ohio State University Wexner Medical Center, Columbus, USA.
Elizabeth O BuschurDivision of Endocrinology, Diabetes, and Metabolism, Ohio State University Wexner Medical Center, Columbus, USA.
Bridgeport Hospital · USCleveland Clinic · USThe Ohio State University Wexner Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInsulin pump use is increasing in frequency among pregnant individuals with type 1 diabetes (T1D). Automated insulin delivery (AID) technologies have not been studied extensively in pregnancy.

methodWe present a retrospective case series of eight individuals with T1D who used the Tandem t:slim X2 insulin pump (Tandem Diabetes Care, Inc., CA, USA) during pregnancy. Weekly continuous glucose monitor and insulin pump data were analyzed from electronic medical records and data-sharing portals. Safety, glycemic control, and pregnancy outcomes were examined with both the control IQ (CIQ) and basal IQ (BIQ) algorithms.

resultsSix CIQ and two BIQ users were studied. The mean glycated hemoglobin (A1C) during pregnancy was 6.1%, and the average time in pregnancy-recommended glycemic range (TIR; 63-140mg/dL) was 67.9%. There were no instances of diabetic ketoacidosis or severe hypoglycemia. CIQ users had a higher mean sensor glucose (127.6 mg/dL) compared to BIQ participants (118.4 mg/dL). However, the average time below range (<63 mg/dL) was 6.1% in BIQ participants compared to 1.5% in CIQ participants. CIQ participants used several strategies to achieve glycemic targets, including daytime use of sleep activity. An increased basal-to-bolus insulin ratio was negatively correlated with TIR (r=-0.415).

conclusionsTandem t:slim X2 insulin pumps were safely used during pregnancy in eight individuals with T1D, with variable success in achieving recommended glycemic targets. Further research is needed to understand differences in CIQ and BIQ use in pregnancy. AID device manufacturers must additionally develop further methods to target lower glucose for pregnant users.

Indexed as

automated insulin deliveryhybrid closed loopinsulin pumppregnancytime in range (tir)type 1 diabetes mellitus (t1d)

Identifiers

PMID38361690
PMCPMC10868538
OpenAlexW4390912879

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.